MRK - Promising HIV Treatment: Phase 2 Clinical Trial Success for Gilead's and Merck's Combo Therapy | Benzinga
Gilead Sciences Inc (NASDAQ:GILD) and Merck & Co Inc (NYSE:MRK) released results from the Phase 2 clinical study evaluating the combination of islatravir and lenacapavir for HIV infection.
At 24 weeks, the investigational combination maintained a high rate (94.2%) of viral suppression (HIV-1 RNA <50 copies/mL), which is a secondary endpoint of the study.
Results of the primary endpoint (HIV-1 RNA ?50 copies/mL (c/mL) showed that one participant (1.9%) treated with islatravir and lenacapavir had a viral load of >50 copies/mL at Week 24; the ...